Please assess the completion status of the following clinical trial:

Trial Title: INB03 for the Treatment of Pulmonary Complications From COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have one or more of the following comorbidities:~   1. Age ≥ 65 years;~  2. Obesity (BMI ≥ 30);~  3. Hypertension (on one or more drugs for treatment of hypertension);~  4. Diabetes (on one or more drugs for Type I or Type II diabetes);~  5. Cardiovascular disease (on one or more drugs for treatment of cardiovascular disease, other than aspirin);~  6. History of congestive heart failure (CHF) or myocardial infarction (MI);~  7. Black or African-American race (at least one parent identifies as Black or African-American);~  8. Hispanic or Latino ethnicity.~2. Have a positive COVID-19 test in the last 28 days;~3. Have room air SaO2 \< 96%, or SpO2 \< 96% on room air at sea level, or PaO2/FiO2 \< 300;~4. Have abnormal chest X-ray, MRI or CT scan consistent with pulmonary complications from COVID-19;~5. Provide written informed consent prior to any study related procedures being performed.~Exclusion Criteria:~Participants will be excluded from the study if 1 or more of the following criteria are applicable at Screening:~1. Age \< 18 years;~2. Require immediate intubation due to advanced respiratory failure - including continuous positive airway pressure (CPAP) and bi-level positive airway pressure (BIPAP);~3. Require immediate admission to an Intensive Care Unit (ICU) for any reason;~4. On therapy with approved TNF inhibitor (eg: infliximab, etanercept, adalimumab, certolizumab pegol, golimumab, thalidomide, etc) in the last 6 months;~5. Being treated with dexamethasone (IV or PO) at a dose of \>15mg per day or solumedrol or equivalent corticosteroid at a dose of \>75mg per day;~6. Taking any medication known to be CCR5 receptor antagonist (eg: leronlimab, aplaviroc, vicriviroc or maraviroc) in the last 6 months;~7. Taking any medication known to inhibit the cytokine pathway (eg: anakinra, tocilizumab, siltuximab, etc) in the last 6 months;~8. Known to be pregnant;~9. Has known HIV, HCV or HBV infection;~10. Has known Mycobacterium tuberculosis infection or evidence of infection on chest X-ray;~11. Significant hepatic disease (ALT/AST\> 4 times the ULN);~12. On therapy for cancer in the last 6 months;~13. On therapy for organ transplant in the last 6 months or on a waiting list for organ transplant, including patients on renal replacement therapy for any reason;~14. Known hypersensitivity to investigational product or its excipients;~15. Participating in an investigational drug or device trial;~16. Congestive heart failure (CHF) or myocardial infarction (MI) diagnosed in the last 2 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo + Standard of Care (Type: PLACEBO_COMPARATOR): Patients will receive placebo + standard medical care
- INB03 + Standard of Care (Type: EXPERIMENTAL): Patients will receive INB03 + standard medical care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy